INmune Bio Inc. develops clinical-stage immunology and biotechnology treatments designed to target the innate immune system in disease. Company news commonly centers on three platforms: CORDStrom, a pooled allogeneic human umbilical cord-derived mesenchymal stromal/stem cell platform; XPro, a dominant-negative TNF platform intended to selectively neutralize soluble TNF; and INKmune, a cell-based medicine designed to prime natural killer cells against residual cancer.
Recurring updates include clinical and preclinical data, regulatory pathway discussions, manufacturing and collaboration agreements, conference presentations, shareholder communications, and quarterly or annual financial results. Coverage also reflects program areas such as recessive dystrophic epidermolysis bullosa, early Alzheimer’s disease, neuroinflammation, inflammatory disease and oncology.
INmune Bio reported its Q2 2022 financial results and business update, highlighting the dosing of the first patient in a Phase II trial for Alzheimer’s using XPro™. The FDA review concerning a clinical hold on XPro1595 is ongoing. The company has sufficient doses for ongoing trials and has presented promising data on XPro™ and INB03 at various conferences. Financially, INmune posted a net loss of $6.8 million, slightly up from $6.7 million last year, with $61.2 million in cash as of June 30, 2022. Shares outstanding are approximately 17.9 million.
INmune Bio, Inc. will host a conference call on August 3, 2022 at 4:30 PM ET to discuss its Q2 2022 results and provide a corporate update. Participants can join by dialing 1-877-407-0784 (or 1-201-689-8560 internationally) and entering conference ID 13728540. The live webcast will also be available. INmune Bio focuses on developing therapies targeting the innate immune system for diseases such as cancer and Alzheimer's.
INmune Bio (NASDAQ: INMB) announces participation in the Alzheimer's Association International Conference and BTIG Biotechnology Conference, focusing on innovative therapies for Alzheimer's disease. RJ Tesi, Ph.D., will engage in panel discussions about novel treatments and the role of inflammation in Alzheimer's. The AAIC panel is part of a program aimed at funding cutting-edge research. The company will also release videos highlighting neuroinflammation's role in disease. INmune Bio's XPro™ aims to reduce neuroinflammation, potentially benefiting Alzheimer's patients.
INmune Bio, Inc. (NASDAQ: INMB) has received U.S. Patent No. 11,365,229 for methods of treating neurological diseases with Dominant Negative Tumor Necrosis Factor (DN-TNF) variants, such as XPro™, allowing these treatments to cross the blood-brain barrier. This patent is valid until September 10, 2033, with a possible extension. The company believes this patent enhances its intellectual property and supports its ongoing clinical trials for conditions like Alzheimer’s disease, treatment-resistant depression, and ALS.
INmune Bio (NASDAQ: INMB) presented data at the HER2 Targeted Therapy Summit, demonstrating that INB03™ effectively decreases MUC4 expression in trastuzumab-resistant HER2+ breast cancer models. This treatment not only reverses resistance to trastuzumab but also enhances the immunologically active tumor microenvironment (TME). Key findings indicate a significant increase in activated natural killer (NK) cells and anti-tumor macrophages when combining INB03 with trastuzumab. The company aims to advance INB03 into a Phase II trial, aiming for improved outcomes in patients with breast cancer resistant to current treatments.
On May 23, 2022, INmune Bio (NASDAQ: INMB) announced that the FDA placed their Investigational New Drug (IND) application for XPro™ in Alzheimer's treatment on clinical hold, pending additional information regarding Chemistry Manufacturing and Controls (CMC). The official hold letter is expected in approximately 30 days. Meanwhile, the Phase 2 trial for XPro™ continues to enroll patients in Australia. XPro™ is designed to inhibit soluble TNF, potentially reducing neuroinflammation in neurologic diseases.
INmune Bio (NASDAQ: INMB) announced that David Moss, CFO, will present at the H.C. Wainwright Global Hybrid Investment Conference from May 23-26, 2022, at the Fontainebleau Hotel in Miami Beach, FL. The presentation is scheduled for May 24, 2022, at 10:00 AM ET. Moss will also be available for one-on-one meetings, which can be requested through the conference registration link. INmune Bio is focused on immunological therapies targeting the innate immune system, with several candidates in clinical trials for various conditions.
INmune Bio announced that data on XPro™'s ability to promote remyelination in a cuprizone model of multiple sclerosis will be presented on May 10, 2022. Research by Professor Lesley Probert reveals that XPro™ enhances macrophage phagocytosis of myelin debris, aiding in the remyelination process. Previous findings have indicated that XPro™ promotes remyelination in Alzheimer’s patients after a successful Phase I trial. This represents a promising development in neurodegenerative disease treatment.
INmune Bio (NASDAQ: INMB) has dosed its first patient in a Phase II trial for XPro1595, targeting mild Alzheimer’s disease. Financial results for Q1 2022 reveal a net loss of $6.9 million, up from $4.6 million the previous year, with revenues of $0.2 million. R&D expenses rose to $4.3 million, while cash reserves stood at $66.7 million as of March 31, 2022. Upcoming milestones include top-line results from pivotal trials expected in 2023, supporting the potential of their DN-TNF and INKmune platforms against various malignancies.
INmune Bio, Inc. (NASDAQ: INMB) is set to host a conference call and webcast on May 5, 2022, at 4:30 PM ET to discuss first-quarter results ending March 31, 2022, and provide a corporate update. The call can be accessed via dial-in numbers and a live audio webcast link. The company develops therapies targeting the innate immune system, with key products in clinical trials for conditions such as cancer and Alzheimer's disease. Investors are advised that outcomes of ongoing clinical trials remain uncertain as they await FDA approvals.